Loading stock data…
OCUL
$9.71-0.06 (-0.61%)
Pre-Market$9.48-0.23 (-2.33%)· Last close May 5
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocular Therapeutix, Inc. in the Healthcare sector is trading at $9.71. The stock is currently 41% below its 52-week high of $16.44, remaining 12.0% below its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why OCUL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.71
Potential Upside
5%
Whystock Fair Value$10.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$26.00+167.8%
Range$18.00 – $34.00
Fundamentals
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.13%
Volume
Today's trading volume
4.14M
Recent News
Ocular Therapeutix Q1 Earnings Call Highlights
Ocular Therapeutix (NASDAQ:OCUL) management used its first-quarter 2026 earnings call to highlight clinical and regulatory progress for AXPAXLI, the company’s investigational therapy for wet age-related macular degeneration (wet AMD), while also outlining next steps for its broader retinal disease p
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year at $10.79 million. Its GAAP loss of $0.40 per share was 20.5% below analysts’ consensus estimates.
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to look for.
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial
Ocular Therapeutix, Inc. recently presented updates at Eyecelerator 2026 in Denver and is now in formal FDA discussions after its SOL-1 Phase 3 trial for AXPAXLI in wet age-related macular degeneration met its primary endpoint with strong statistical significance and a favorable safety profile. The company is preparing an NDA for AXPAXLI while planning independent commercialization backed by patent protection to 2044, scalable hydrogel manufacturing and the potential for a first-in-category...